Congress makes pharmacy benefit managers legally accountable to patients

What it does

This bill amends ERISA to classify pharmacy benefit managers (PBMs) as fiduciaries when they manage drug networks, negotiate rebates, or process claims for employer health plans. It requires PBMs to disclose all compensation they receive (direct and indirect) and prohibits them from indemnifying themselves against liability for breaching fiduciary duties. The effect: PBMs must act in the interest of plan members rather than their own profit, and injured parties can sue them directly for conflicts of interest.

Why we flagged it

The bill's core mechanism is reclassifying PBMs as ERISA fiduciaries and stripping them of indemnification protections. This is a regulatory accountability measure, not a subsidy, tax break, or commemorative act. It shifts legal liability and disclosure obligations onto an intermediary industry.

What the text implies

• PBMs may respond by raising fees to plan sponsors or reducing rebate pass-through to plans, shifting costs to employers and ultimately employees rather than reducing their own profit margins.
• Fiduciary status may incentivize PBMs to exit certain markets (small employers, high-risk populations) where litigation risk outweighs revenue, potentially reducing plan choice.
• The 12-month implementation window is tight; PBMs may challenge the rule in court, delaying enforcement and creating uncertainty for plan sponsors about compliance obligations.
• Disclosure requirements may reveal PBM compensation structures that are currently opaque, potentially triggering legislative or regulatory backlash and further restrictions.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Employer plan members gain enforceable legal rights against PBMs that have historically negotiated rebates and formularies in ways that prioritize PBM profit over drug access and affordability. Fiduciary status and liability exposure create incentives for PBMs to disclose conflicts and reduce self-dealing.

Who stands to gain

• Plaintiff's bar (litigation against PBMs)
• Employer plan sponsors (potential rebate recovery through litigation)
• Plan members (access to remedies for PBM self-dealing)

Named in the bill

Pharmacy Benefit Managers (PBMs), ERISA (Employee Retirement Income Security Act of 1974), Group health plans, Plan sponsors, Plan administrators, Health insurance issuers, Drug manufacturers, Drug distributors, Wholesalers, Rebate aggregators, Group purchasing organizations

Where it stands

3 cosponsors: 2 Democrats, 1 Republicans.

• Dec 17, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Dec 17, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

5 lobbying clients named this bill on 5 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $3,899,179 in lobbying spend. A filing names 29 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 78% of bills with at least one filing.

Roger Marshall, the sponsor, reported $1,849,491 in PAC receipts in the 2026 cycle.

• Pharmaceutical Care Management Association — $3,282,990 on 1 filing
• Cystic Fibrosis Foundation — $270,000 on 1 filing
• National Community Pharmacists Association — $270,000 on 1 filing
• National Multiple Sclerosis Society — $66,189 on 1 filing
• U.S. Public Interest Research Group — $10,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.